Head to Head Survey: Entrada Therapeutics (NASDAQ:TRDA) & Rani Therapeutics (NASDAQ:RANI)

Entrada Therapeutics (NASDAQ:TRDA) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Valuation and Earnings

This table compares Entrada Therapeutics and Rani Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42 million	9.73	-$143.75 million	($3.96)	-1.60
Rani Therapeutics	$1.63 million	67.65	-$29.67 million	($0.27)	-2.93

Rani Therapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Entrada Therapeutics and Rani Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Rani Therapeutics	N/A	-104.60%	-65.17%

Volatility and Risk

Entrada Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Insider & Institutional Ownership

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Entrada Therapeutics and Rani Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1	1	4	0	2.50
Rani Therapeutics	1	0	4	1	2.83

Entrada Therapeutics presently has a consensus price target of $17.75, suggesting a potential upside of 179.53%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 1,006.19%. Given Rani Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Entrada Therapeutics.

Summary

Rani Therapeutics beats Entrada Therapeutics on 9 of the 14 factors compared between the two stocks.

About Entrada Therapeutics

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.